Related references
Note: Only part of the references are listed.Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis
Frank Kloprogge et al.
PLOS MEDICINE (2018)
Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy
Clifford G. Banda et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria
Jesmin Lohy Das et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin
Olusola Olafuyi et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women
Ritah F. Mutagonda et al.
MALARIA JOURNAL (2017)
MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy
Karin Vos et al.
PHARMACOGENOMICS (2017)
Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers
Jay Prakash Jain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients
B. A. Maganda et al.
PHARMACOGENOMICS JOURNAL (2016)
Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women
Ritah F. Mutagonda et al.
MALARIA JOURNAL (2016)
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data
BMC MEDICINE (2015)
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment
Betty A. Maganda et al.
MALARIA JOURNAL (2015)
Investigation of the Functional Role of P-Glycoprotein in Limiting the Oral Bioavailability of Lumefantrine
Wahajuddin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Population Pharmacokinetics and Clinical Response for Artemether-Lumefantrine in Pregnant and Nonpregnant Women with Uncomplicated Plasmodium falciparum Malaria in Tanzania
Dominic Mosha et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
E. Ngaimisi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment
Mohammed Lamorde et al.
AIDS (2013)
Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and N-Acetyltransferase 2 Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania
Eva Maria Staehli Hodel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda
Joel Tarning et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients
A. Habtewold et al.
PHARMACOGENOMICS JOURNAL (2013)
Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem
Kathrin Klein et al.
Frontiers in Genetics (2013)
Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda
F. Kloprogge et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Potential P-Glycoprotein-Mediated Drug-Drug Interactions of Antimalarial Agents in Caco-2 cells
Enoche F. Oga et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2012)
Concomitant Efavirenz Reduces Pharmacokinetic Exposure to the Antimalarial Drug Artemether-Lumefantrine in Healthy Volunteers
Liusheng Huang et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
Pauline Byakika-Kibwika et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians
E. Gebeyehu et al.
PHARMACOGENOMICS JOURNAL (2011)
Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes
Hyunyoung Jeong
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria
Stephen J. Rogerson et al.
LANCET INFECTIOUS DISEASES (2010)
Genetic Variations in ABCB1 and CYP3A5 as well as Sex Influence Quinine Disposition Among Ugandans
Jackson K. Mukonzo et al.
THERAPEUTIC DRUG MONITORING (2010)
The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem®) for acute uncomplicated Plasmodium falciparum malaria
Steffen Borrmann et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2010)
Population Pharmacokinetics of Lumefantrine in Pregnant Women Treated with Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria
Joel Tarning et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Multiplexed Real-Time PCR Assay for Discrimination of Plasmodium Species with Improved Sensitivity for Mixed Infections
Sandra E. Shokoples et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2)
Anne Liljander et al.
MALARIA JOURNAL (2009)
Understanding the pharmacokinetics of Coartem (R)
Abdoulaye Djimde et al.
MALARIA JOURNAL (2009)
Clinical pharmacology of artemisinin-based combination therapies
Francesca T. Aweeka et al.
CLINICAL PHARMACOKINETICS (2008)
4β-Hydroxycholesterol is a new endogenous CYP3A marker:: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
Ulf Diczfalusy et al.
PHARMACOGENETICS AND GENOMICS (2008)
Simplified antimalarial therapeutic monitoring: using the day-7 drug level?
Nicholas J. White et al.
TRENDS IN PARASITOLOGY (2008)
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria
Rose McGready et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation
M. Sun et al.
PLACENTA (2006)
P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages
AA Mathias et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2005)
Pregnancy-induced changes in pharmacokinetics - A mechanistic-based approach
GD Anderson
CLINICAL PHARMACOKINETICS (2005)
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
JA Williams et al.
DRUG METABOLISM AND DISPOSITION (2002)
Share Paper
